Disease · MONDO_0010481

angioedema

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. angioedema. Diseases, record MONDO_0010481. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0010481

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: angioedema; Open Targets
Open Targets ID: MONDO_0010481; Open Targets
Other names: Edemas, angioneurotic, Quincke edema, Quincke oedema, Quincke's edema, Quincke's oedema, Quinckes edema, Quinckes oedema, Urticarias, giant, angioedemas, angioneurotic Edemas, edema, Quincke's, edema, angioneurotic, giant Urticarias, giant urticaria, urticaria, giant; Open Targets
Disease Ontology: DOID:1558; Disease Ontology
MeSH: D000799; MeSH
Highest stage of its drugs: Approval, for 5 of its 14 drugs, from DailyMed and PMDA; Open Targets

Drugs14

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ICATIBANT ACETATE	CHEMBL2028852	Protein	Approval	DailyMed and PMDA	4	1	1	Drugs and targets
BEROTRALSTAT HYDROCHLORIDE	CHEMBL6067995	Small molecule	Approval	PMDA	2	0	0	Drugs and targets
CARBINOXAMINE MALEATE	CHEMBL1200974	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
DEXCHLORPHENIRAMINE MALEATE	CHEMBL1200927	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
EPINEPHRINE	CHEMBL679	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
CONESTAT ALFA	CHEMBL2108350	Protein	Phase 3	ClinicalTrials.gov	3	2	2	Drugs and targets
ICATIBANT	CHEMBL2028850	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
HUMAN C1-ESTERASE INHIBITOR	CHEMBL4297549	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
OMALIZUMAB	CHEMBL1201589	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM CHLORIDE	CHEMBL1200574	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 14

See all 14 drugs

Targets19

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KLKB1	Plasma kallikrein	4	Plasma kallikrein inhibitor	Approval	https://conductscience.org/library/genes/3818	Drugs and targets
BDKRB2	B2 bradykinin receptor	2	Bradykinin B2 receptor antagonist	Approval	https://conductscience.org/library/genes/624	Drugs and targets
HRH1	Histamine H1 receptor	2	Histamine H1 receptor antagonist	Approval	https://conductscience.org/library/genes/3269	Drugs and targets
ADRA1A	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/146	Drugs and targets
ADRA2A	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/152	Drugs and targets
ADRB1	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets

1 to 10 of 19

See all 19 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01919801	Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema	Phase 3	118	2016-10-10	Angiotensin Converting Enzyme Inhibitor Induced Angioedema	ICATIBANT	Its record names the disease	ClinicalTrials.gov
NCT01723072	Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy	Phase 3	91	2020-09-09	Chronic Spontaneous Urticaria, Angioedema	OMALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01343823	Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema	Phase 2	79	2013-11-18	ACE Inhibitor Induced Angioedema	ECALLANTIDE	Its record names the disease	ClinicalTrials.gov
NCT01188564	Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks	Phase 3	75	2015-08-07	Hereditary Angioedema	CONESTAT ALFA	Its record names the disease	ClinicalTrials.gov
NCT01036659	Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema	Phase 2	50		Angioedema	ECALLANTIDE	Its record names the disease	ClinicalTrials.gov
NCT01843530	Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema	Phase 3	31		Acute ACE-induced Angioedema	HUMAN C1-ESTERASE INHIBITOR	Its record names the disease	ClinicalTrials.gov
NCT06679426	Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema	Phase 3	24		ACE Inhibitor-Induced Angioedema	CONESTAT ALFA, SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00517582	Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema	Phase 1	13		Angioneurotic Edema	ICATIBANT ACETATE	Its record names the disease	ClinicalTrials.gov
NCT01154361	AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study	Phase 2			Angioedema	ICATIBANT	Its record names the disease	ClinicalTrials.gov
NCT07216378	Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat				Hereditary Angioedema	SEBETRALSTAT	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Icatibant 30 mg vs Placebo: Number of Participants With Clinically Significant Changes in Laboratory Evaluation, Vital Signs, Electrocardiogram (ECG) and Physical Examination	0 of 60	0 of 58	118	NCT01919801	Trial comparisons
Icatibant 30 mg vs Placebo: Number of Participants Experienced ACE-I-induced Angioedema Attack Following Study Drug Administration	35 of 60	35 of 58	118	NCT01919801	Trial comparisons
Icatibant 30 mg vs Placebo: Number of Participants Experienced Airway Intervention Due to ACE-I-induced Angioedema	1 of 60	0 of 58	118	NCT01919801	Trial comparisons
Icatibant 30 mg vs Placebo: Number of Participants Admitted to Hospital or Intensive Care Unit (ICU)	22 of 60	22 of 58	118	NCT01919801	Trial comparisons
Icatibant 30 mg vs Placebo: serious adverse events	2 of 60	1 of 58	118	NCT01919801	Trial comparisons
Omalizumab vs Placebo: serious adverse events	4 of 44	2 of 47	91	NCT01723072	Trial comparisons
rhC1INH vs Placebo (Saline): serious adverse events	1 of 56	0 of 18	74	NCT01188564	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
28552382	RESULT	1	PubMed
25182544	RESULT	1	PubMed
42159953	DERIVED	1	PubMed
27010957	DERIVED	1	PubMed
25629740	DERIVED	1	PubMed
25601538	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0010481

GET https://conductscience.org/api/diseases/v1/MONDO_0010481/drugs

API reference For AI assistants